Site search2019
- 2019.12.24PRThe paper on TLR9 agonist published in the Journal of Controlled Release（938KB）
- 2019.12.24NewsBrightPath Concludes Agreements with Osaka University, BIKEN Foundation and Teikyo University for Development of TLR9 Agonist Lipid-Nucleic Acid as Immuno-stimulator（227KB）
- 2019.8.19NewsShinshu University and BrightPath Conclude Joint R&D Agreement for CAR-T Cell Therapy for Solid Tumors（1456KB）
- 2019.8.9IRAnnouncement on the Results of a Phase I Clinical Trial in Melanoma for Cancer Peptide Vaccine GRN-1201（185KB）
- 2019.5.10IRFinancial Results for the Fiscal Year ended March 31, 2019 [Japanese GAAP]（347KB）
- 2019.3.15IRAnnouncement on the Waiver of Claims for a Subsidiary, Shift to Non-consolidated Settlement of Accounts, and Disclosure of Forecast for Non-consolidated Financial Results（112KB）
- 2019.8.9IRAnnouncement on the Results of a Phase I Clinical Trial in Melanoma for Cancer Peptide Vaccine GRN-1201（185KB）
- 2019.5.10IRFinancial Results for the Fiscal Year ended March 31, 2019 [Japanese GAAP]（347KB）
- 2019.3.15IRAnnouncement on the Waiver of Claims for a Subsidiary, Shift to Non-consolidated Settlement of Accounts, and Disclosure of Forecast for Non-consolidated Financial Results（112KB）
- 2019.12.24NewsBrightPath Concludes Agreements with Osaka University, BIKEN Foundation and Teikyo University for Development of TLR9 Agonist Lipid-Nucleic Acid as Immuno-stimulator（227KB）
- 2019.8.19NewsShinshu University and BrightPath Conclude Joint R&D Agreement for CAR-T Cell Therapy for Solid Tumors（1456KB）
- 2019.12.24PRThe paper on TLR9 agonist published in the Journal of Controlled Release（938KB）